Regenerative medicine company ViaCyte said today that the first patients have been implanted in a trial of its islet cell replacement therapy, PEC-Direct.
San Diego-based ViaCyte is developing the cell therapy as a functional cure for patients with Type I diabetes who are at risk of suffering acute life-threatening complications.
Get the full story at our sister site, Drug Delivery Business News.
The post ViaCyte launches cell replacement trial for Type I diabetes appeared first on MassDevice.